Generics in North America
Generics in North America Summary Generics in North America industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and... もっと見る
SummaryGenerics in North AmericaSummary Generics in North America industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2019-24, and forecast to 2029). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Key Highlights - A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists. - The North American generics market recorded revenues of $89.2 billion in 2024, representing a compound annual growth rate (CAGR) of 4.6% between 2019 and 2024. - Market consumption volume increased with a CAGR of 0.8% between 2019 and 2024, reaching a total of 84.8% of total pharma volume in 2024. - In 2024, the revenue of the North American generics market experienced an annual growth of 5.1%. The market’s growth is driven by the rising prevalence of chronic diseases such as diabetes, hypertension, and cardiovascular conditions, increasing the demand for affordable, long-term medications. Scope - Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in North America - Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in North America - Leading company profiles reveal details of key generics market players’ global operations and financial performance - Add weight to presentations and pitches by understanding the future growth prospects of the North America generics market with five year forecasts by both value and volume Reasons to Buy - What was the size of the North America generics market by value in 2024? - What will be the size of the North America generics market in 2029? - What factors are affecting the strength of competition in the North America generics market? - How has the market performed over the last five years? - Who are the top competitors in North America's generics market? Table of ContentsTable of Contents1 Executive Summary 1.1. Market value 1.2. Market value forecast 1.3. Market volume 1.4. Market volume forecast 1.5. Geography segmentation 1.6. Market rivalry 1.7. Competitive landscape 2 Market Overview 2.1. Market definition 2.2. Market analysis 3 Market Data 3.1. Market value 3.2. Market volume 4 Market Segmentation 4.1. Geography segmentation 5 Market Outlook 5.1. Market value forecast 5.2. Market volume forecast 6 Five Forces Analysis 6.1. Summary 6.2. Buyer power 6.3. Supplier power 6.4. New entrants 6.5. Threat of substitutes 6.6. Degree of rivalry 7 Competitive Landscape 7.1. Who are the leading players? 7.2. What strategies do the leading players follow? 7.3. What are the most recent developments in the market? 8 Company Profiles 8.1. Teva Pharmaceutical Industries Ltd 8.2. Viatris Inc 8.3. Pfizer Inc 8.4. Sandoz Group AG 9 Macroeconomic Indicators 9.1. Country data 10 Appendix 10.1. Methodology 10.2. Industry associations 10.3. Related MarketLine research 10.4. About MarketLine List of Tables/GraphsList of TablesTable 1: North America generics market value: $ million, 2019-24 Table 2: North America generics market volume: % of total pharma volume, 2019-24 Table 3: North America generics market geography segmentation: $ million, 2024 Table 4: North America generics market value forecast: $ million, 2024-29 Table 5: North America generics market volume forecast: % of total pharma volume, 2024-29 Table 6: Teva Pharmaceutical Industries Ltd: Key Facts Table 7: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios Table 8: Teva Pharmaceutical Industries Ltd: Key Employees Table 9: Viatris Inc: Key Facts Table 10: Viatris Inc: Annual Financial Ratios Table 11: Viatris Inc: Key Employees Table 12: Pfizer Inc: Key Facts Table 13: Pfizer Inc: Annual Financial Ratios Table 14: Pfizer Inc: Key Employees Table 15: Pfizer Inc: Key Employees Continued Table 16: Sandoz Group AG: Key Facts Table 17: Sandoz Group AG: Annual Financial Ratios Table 18: Sandoz Group AG: Key Employees Table 19: North America Exchange Rate, 2019-24
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医薬)の最新刊レポート
MarketLine社の Pharmaceuticals and Healthcare分野 での最新刊レポート本レポートと同じKEY WORD(generics)の最新刊レポート
よくあるご質問MarketLine社はどのような調査会社ですか?マーケットライン(MarketLine)は、世界の企業を幅広く対象に様々な角度から調査した企業レポートも出版しています。 マーケットライン(MarketLine)はGlobalDataの... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|